↓ Skip to main content

Chronic migraine plus medication overuse headache: two entities or not?

Overview of attention for article published in The Journal of Headache and Pain, September 2011
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
90 Dimensions

Readers on

mendeley
95 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Chronic migraine plus medication overuse headache: two entities or not?
Published in
The Journal of Headache and Pain, September 2011
DOI 10.1007/s10194-011-0388-3
Pubmed ID
Authors

Andrea Negro, Paolo Martelletti

Abstract

Chronic migraine (CM) represents migraine natural evolution from its episodic form. It is realized through a chronicization phase that may require months or years and varies from patient to patient. The transition to more frequent attacks pattern is influenced by lifestyle, life events, comorbid conditions and personal genetic terrain, and it often leads to acute drugs overuse. Medication overuse headache (MOH) may complicate every type of headache and all the drugs employed for headache treatment can cause MOH. The first step in the management of CM complicated by medication overuse must be the withdrawal of the overused drugs and a detoxification treatment. The goal is not only to detoxify the patient and stop the chronic headache but also to improve responsiveness to acute or prophylactic drugs. Different methods have been suggested: gradual or abrupt withdrawal; home treatment, hospitalization, or a day-hospital setting; re-prophylaxes performed immediately or at the end of the wash-out period. Up to now, only topiramate and local injection of onabotulinumtoxinA have shown efficacy as therapeutic agents for re-prophylaxis after detoxification in patients with CM with and without medication overuse. Although the two treatments showed similar efficacy, onabotulinumtoxinA is associated with a better adverse events profile. Recently, the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program proved that patients with CM, even those with MOH, are the ones most likely to benefit from onabotulinumtoxinA treatment. Furthermore, it provided an injection paradigm that can be used as a guide for a correct administration of onabotulinumtoxinA.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Netherlands 1 1%
Denmark 1 1%
Brazil 1 1%
Unknown 91 96%

Demographic breakdown

Readers by professional status Count As %
Other 11 12%
Student > Master 11 12%
Researcher 11 12%
Student > Postgraduate 10 11%
Student > Ph. D. Student 10 11%
Other 20 21%
Unknown 22 23%
Readers by discipline Count As %
Medicine and Dentistry 36 38%
Neuroscience 9 9%
Psychology 6 6%
Nursing and Health Professions 4 4%
Agricultural and Biological Sciences 3 3%
Other 11 12%
Unknown 26 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2012.
All research outputs
#19,244,099
of 23,849,058 outputs
Outputs from The Journal of Headache and Pain
#1,210
of 1,417 outputs
Outputs of similar age
#110,880
of 132,741 outputs
Outputs of similar age from The Journal of Headache and Pain
#11
of 12 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,417 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 132,741 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.